Medication Monitor

Generic Name (Trade Name—Company)
February 1, 2011


(Viibryd—Clinical Data)
Treatment of depression


Treatment of major depressive disorder (MDD) in adults

Vilazodone has a unique mechanism of action because it is a selective serotonin reuptake inhibitor (SSRI) and a partial agonist at the 5HT1A receptor. Although the net result of this action on serotonergic transmission is not fully understood, experts have theorized that the partial agonist activity of vilazodone may decrease the occurrence of sexual adverse effects that are commonly associated with SSRIs. FDA approved the antidepressant based on two Phase III, 8-week, placebo-controlled trials involving 869 patients with MDD age 18 to 70 years showed that treatment with vilazodone 40 mg once daily was superior to placebo in the improvement of depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale total score. Some of the most common adverse events with vilazodone were diarrhea, nausea, vomiting, and insomnia